Factor inhibiting HIF (FIH) is an asparagine hydroxylase that acts on hypoxia inducible factors (HIFs) to control cellular adaptation to hypoxia. FIH is expressed in several tumor types, but its impact in tumor progression remains largely unexplored. We observed that FIH was expressed on human lung cancer tissue. Deletion of FIH in mouse and human lung cancer cells resulted in an increased glycolytic metabolism, consistent with increased HIF activity. FIH-deficient lung cancer cells exhibited decreased proliferation. Analysis of RNA-seq data confirmed changes in the cell cycle and survival, and revealed molecular pathways that were dysregulated in the absence of FIH including the upregulation of angiomotin (Amot), a key component of the Hippo tumor suppressor pathway. We show that FIH-deficient tumors were characterized by higher immune infiltration of NK and T cells compared to FIH competent tumor cells. In vivo studies demonstrated that FIH deletion resulted in reduced tumor growth and metastatic capacity. Moreover, high FIH expression correlated with poor overall survival in non-small cell lung cancer (NSCLC). Together, our data unravel FIH as a therapeutic target for the treatment of lung cancer.
Ana García-del Río, Endika Prieto-Fernández, Leire Egia-Mendikute, Asier Antoñana-Vildosola, Borja Jimenez-Lasheras, So Young Lee, Adrián Barreira-Manrique, Samanta Romina Zanetti, Ander de Blas, Paloma Velasco-Beltrán, Alexandre Bosch, Ana M. Aransay, Asis Palazon